Introduction
death, AZD7442, Tixagevimab-cilgavimab
The COVID-19 pandemic caused by SARS-CoV-2 continues, and therapies that prevent hospitalization and/or death have received US Food and Drug Administration emergency use authorization, including monoclonal antibodies (mAbs) and direct-acting antivirals.AZD7442 is a combination of 2 anti–SARS-CoV-2 mAbs, tixagevimab (AZD8895) and cilgavimab (AZD1061), both derived from persons recovered from COVID-19. Tixagevimab-cilgavimab administered by IM gluteal injection previously received a US Food and Drug Administration emergency use authorization for preexposure prophylaxis.